183 related articles for article (PubMed ID: 34226696)
1. Implications of sex-related differences in central nervous system disorders for drug research and development.
Butlen-Ducuing F; Balkowiec-Iskra E; Dalla C; Slattery DA; Ferretti MT; Kokras N; Balabanov P; De Vries C; Mellino S; Santuccione Chadha A
Nat Rev Drug Discov; 2021 Dec; 20(12):881-882. PubMed ID: 34226696
[No Abstract] [Full Text] [Related]
2. Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges.
Geerts H; Wikswo J; van der Graaf PH; Bai JPF; Gaiteri C; Bennett D; Swalley SE; Schuck E; Kaddurah-Daouk R; Tsaioun K; Pelleymounter M
CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):5-20. PubMed ID: 31674729
[TBL] [Abstract][Full Text] [Related]
3. Artificial intelligence in pharmaceutical research and development.
Mitchell JB
Future Med Chem; 2018 Jul; 10(13):1529-1531. PubMed ID: 29966438
[No Abstract] [Full Text] [Related]
4. Digital phenotyping approaches and mobile devices enhance CNS biopharmaceutical research and development.
Smith DG
Neuropsychopharmacology; 2018 Dec; 43(13):2504-2505. PubMed ID: 30267015
[No Abstract] [Full Text] [Related]
5. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
Cole PE; Schwarz AJ; Schmidt ME
Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
[TBL] [Abstract][Full Text] [Related]
6. Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration.
Brunner D; Balcı F; Ludvig EA
Behav Processes; 2012 Feb; 89(2):187-95. PubMed ID: 22155361
[TBL] [Abstract][Full Text] [Related]
7. Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review.
Sahu JK; Mishra AK
Curr Mol Pharmacol; 2018; 11(4):270-278. PubMed ID: 30129422
[TBL] [Abstract][Full Text] [Related]
8. CNS drug development - lost in translation?
Talevi A; Bellera CL; Di Ianni M; Gantner M; Bruno-Blanch LE; Castro EA
Mini Rev Med Chem; 2012 Sep; 12(10):959-70. PubMed ID: 22420574
[TBL] [Abstract][Full Text] [Related]
9.
Moreno MJ; Ling B; Stanimirovic DB
Expert Opin Drug Discov; 2020 Aug; 15(8):903-915. PubMed ID: 32396023
[TBL] [Abstract][Full Text] [Related]
10. Quality by design in lead optimization: a new strategy to address productivity in drug discovery.
Rossi T; Braggio S
Curr Opin Pharmacol; 2011 Oct; 11(5):515-20. PubMed ID: 21652263
[TBL] [Abstract][Full Text] [Related]
11. Small molecules as central nervous system therapeutics: old challenges, new directions, and a philosophic divide.
Banks WA; Greig NH
Future Med Chem; 2019 Mar; 11(6):489-493. PubMed ID: 30912980
[No Abstract] [Full Text] [Related]
12. CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?
Hutson PH; Clark JA; Cross AJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():171-187. PubMed ID: 27575715
[TBL] [Abstract][Full Text] [Related]
13. Role of Academic Drug Discovery in the Quest for New CNS Therapeutics.
Yokley BH; Hartman M; Slusher BS
ACS Chem Neurosci; 2017 Mar; 8(3):429-431. PubMed ID: 28195461
[TBL] [Abstract][Full Text] [Related]
14. Overview of the use of transgenic animals in CNS drug discovery.
Nestler EJ; Olivier B
Curr Protoc Pharmacol; 2001 May; Chapter 5():Unit5.20. PubMed ID: 21965073
[TBL] [Abstract][Full Text] [Related]
15. The value of PET ligand discovery to CNS drug development.
Schmidt ME; Andrés JI
Future Med Chem; 2017 Mar; 9(4):351-356. PubMed ID: 28263084
[No Abstract] [Full Text] [Related]
16. Editorial: nitric oxide: implications for the etiology and treatment of central nervous system disorders.
Di Giovanni G
CNS Neurol Disord Drug Targets; 2011 Nov; 10(7):764-5. PubMed ID: 21999727
[No Abstract] [Full Text] [Related]
17. Reverse and Forward Translational Neuropharmacology in Psychiatric Drug Discovery.
Shaffer CL
Clin Pharmacol Ther; 2018 Feb; 103(2):193-195. PubMed ID: 29076553
[TBL] [Abstract][Full Text] [Related]
18. Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics.
van den Brink WJ; Hankemeier T; van der Graaf PH; de Lange ECM
Expert Opin Drug Discov; 2018 Jun; 13(6):539-550. PubMed ID: 29519169
[TBL] [Abstract][Full Text] [Related]
19. Drug Development for Central Nervous System Diseases Using In vitro Blood-brain Barrier Models and Drug Repositioning.
Morofuji Y; Nakagawa S
Curr Pharm Des; 2020; 26(13):1466-1485. PubMed ID: 32091330
[TBL] [Abstract][Full Text] [Related]
20. Does obesity and diabetes mellitus metastasize to the brain? "Metaboptosis" and implications for drug discovery and development.
McIntyre RS; Rong C; Mansur RB; Brietzke E
CNS Spectr; 2019 Oct; 24(5):467-469. PubMed ID: 30940233
[No Abstract] [Full Text] [Related]
[Next] [New Search]
